Different skin thinning potential of equipotent medium-strength glucocorticoids

Skin Pharmacology and Applied Skin Physiology

Volumn 15, Issue 2, 2002, Pages 85-91

  Korting, Hans Christian ^a   Unholzer, Angela ^a   Schäfer Korting, Monika ^b   Tausch, Irene ^c   Gassmueller, Johannes ^c   Nietsch, Karl Heinz ^d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c BioSkin Institut für Dermatologische Forschung und Entwicklung GmbH   (Germany)

^d SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Benefit risk ratio; Betamethasone 17 valerate; Cutaneous sonography; Mometasone furoate; Prednicarbate; Skin atrophy; Topical glucocorticoids

Indexed keywords

BETAGALEN; BETAMETHASONE VALERATE; GLUCOCORTICOID; MOMETASONE FUROATE; PLACEBO; PREDNICARBATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG POTENCY; ECHOGRAPHY; EPIDERMIS; FEMALE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SKIN ATROPHY; SKIN SURFACE; SKINFOLD THICKNESS; TELANGIECTASIA; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS; ATROPHY; BETAMETHASONE 17-VALERATE; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PREDNISOLONE; PREGNADIENEDIOLS; SKIN;

EID: 0036184537     PISSN: 14222868     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049394     Document Type: Article

References (37)

1. Effect of topically applied compound F in selected dermatoses
2. Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept
3. Qualitative and quantitative assessment of the benefit-risk ratio of medium potency topical corticosteroids in vitro and in vivo. Characterisation of drugs with an increased benefit-risk ratio
4. Atrophic striae in patients with inguinal intertrigo
5. Topical glucocorticoids with improved benefit/risk ratio: Do they exist?
6. 0.25% Prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream
7. Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids
8. Preatrophy: Covert sign of thinned skin
9. Comparison of xeroradiographic and ultrasound detection of corticosteroid induced dermal thinning
10. Skin thickness measurement by pulsed ultrasound: Its reproducibility, validation and variability
11. A 50-MHz high-resolution ultrasound imaging system for dermatology
12. Der stellenwert der 20, 50 und 100 MHz sonographie in der dermatologie
13. Bildgebende verfahren in der dermatologie
14. Stylus method for skin surface contour measurement
15. 0.05% Clobetasol 17-propionate cream and ointment but not the corresponding 0.1% triamcinolone acetonide preparations increase skin surface roughness: A possible dissociation of unwanted epidermal and dermal effects
16. Assessment of the atrophogenicity potential of corticosteroids by ultrasound and by biopsy under occlusive and nonocclusive conditions
17. Topical glucocorticoids of the non-fluorinated double-ester type. Lack of atrophogenicity in normal skin as assessed by high-frequency ultrasound
18. In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new
19. Potency assessment of topical corticoids in the vasoconstrictor assay and on tuberculin induced inflammation
20. Influence of corticosteroids on ultraviolet light erythema and pigmentation in man
21. Management of atopic dermatitis with prednicarbate emollient cream 0.1%, a non-halogenated prednisolone derivative
22. Prednicarbate 0.25% ointment in the treatment of atopic dermatitis: A vehicle-controlled double-blind study
23. Controlled studies of intraindividual and interindividual design for comparing corticosteroids clinically
24. Prednicarbate: Dose-response relations in animal models
25. Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts
26. Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin
27. Glucocorticoid receptors in human synovial tissue and relative receptor affinities of glucocorticoid 21-esters
28. Cutaneous inflammation and proliferation in vitro: Differential effects and mode of action of topical glucocorticoids
29. The effect of hydrocortisone aceponate on proliferation, total protein synthesis and collagen synthesis in human skin fibroblasts in vitro
30. Differential effect of medium potent nonhalogenated double-ester-type and conventional glucocorticoids on proliferation and chemotaxis of fibroblasts in vitro
31. Glucocorticoid receptor β, a potential endogenous inhibitor of glucocorticoid actions in humans
32. Inhibition of mineral corticoid activity by the beta-isoform of the human glucocorticoid receptor
33. Comparison of the effects of calcipotriol, prednicarbate and clobetasol 17-propionate on normal skin assessed by ultrasound measurement of skin thickness
34. Steroidbedingte gesichtshautschädigungen nach anwendung von prednicarbat
35. Solid lipid nanoparticles as drug carriers for topical glucocorticoids
36. Liposome preparations - A step forward in topical drug therapy for skin disease. A review
37. Liposome encapsulation improves efficacy of betamethasone dipropionate in atopic eczema but not in psoriasis vulgaris